We are live on
!
Find out more
II
Ishara Investments Portfolio holdings
AUM
$136M
Turnover
52.83%
This Fund
S&P 500
This Quarter
Est. Return
+85.41%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$87.5M
AUM Growth
–
Cap. Flow
+$76.3M
Cap. Flow
% of AUM
87.26%
Top 10 Holdings %
Top 10 Hldgs %
55.95%
Holding
38
New
38
Increased
–
Reduced
–
Closed
–
Avg Time Held Equity + Options
0
years
Top 10 Avg Time Held Equity + Options
0
years
Top 20 Avg Time Held Equity + Options
0
years
Avg Time Held Equity only
0
years
Top 10 Avg Time Held Equity only
0
years
Top 20 Avg Time Held Equity only
0
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Praxis Precision Medicines
PRAX
|
+$7.45M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$6.3M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$5.44M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$3.82M |
| 5 |
Amicus Therapeutics
FOLD
|
+$3.54M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.09% |
| 2 | Industrials | 2.16% |
| 3 | Miscellaneous | 1.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Praxis Precision Medicines
PRAX
$6.75B
| $11.8M | 13.48% |
+40,000
| New | +$7.45M |
2025 Q4
0 quarters
|
|
|
2
Xeris Biopharma Holdings
XERS
$1.88B
| $6.28M | 7.18% |
+800,000
| New | +$6.3M |
2025 Q4
0 quarters
|
|
|
3
BioMarin Pharmaceuticals
BMRN
$10.6B
| $5.94M | 6.8% |
+100,000
| New | +$5.44M |
2025 Q4
0 quarters
|
|
|
4
DELISTED
Amicus Therapeutics
FOLD
| $5.13M | 5.86% |
+360,000
| New | +$3.54M |
2025 Q4
0 quarters
|
|
|
5
Acadia Pharmaceuticals
ACAD
$3.29B
| $4.27M | 4.89% |
+160,000
| New | +$3.82M |
2025 Q4
0 quarters
|
|
6
Annexon
ANNX
$646M
| $3.77M | 4.31% |
+750,000
| New | +$2.87M |
2025 Q4
0 quarters
|
|
7
Nuvation Bio
NUVB
$1.56B
| $3.58M | 4.1% |
+400,000
| New | +$2.48M |
2025 Q4
0 quarters
|
|
8
BridgeBio Pharma
BBIO
$13B
| $2.75M | 3.15% |
+36,000
| New | +$2.36M |
2025 Q4
0 quarters
|
|
9
PTC Therapeutics
PTCT
$4.94B
| $2.73M | 3.13% |
+36,000
| New | +$2.62M |
2025 Q4
0 quarters
|
|
10
United Therapeutics
UTHR
$22.9B
| $2.68M | 3.06% |
+5,500
| New | +$2.56M |
2025 Q4
0 quarters
|
|
11
BioCryst Pharmaceuticals
BCRX
$1.99B
| $2.34M | 2.68% |
+300,000
| New | +$2.17M |
2025 Q4
0 quarters
|
|
12
Vaxcyte
PCVX
$10B
| $2.31M | 2.64% |
+50,000
| New | +$2.24M |
2025 Q4
0 quarters
|
|
13
Genmab
GMAB
$22.8B
| $2.16M | 2.47% |
+70,000
| New | +$2.18M |
2025 Q4
0 quarters
|
|
14
Syndax Pharmaceuticals
SNDX
$1.15B
| $2.1M | 2.4% |
+100,000
| New | +$1.74M |
2025 Q4
0 quarters
|
|
15
Verastem
VSTM
$783M
| $2.08M | 2.38% |
+270,000
| New | +$2.41M |
2025 Q4
0 quarters
|
|
16
Tarsus Pharmaceuticals
TARS
$3.19B
| $1.97M | 2.25% |
+24,000
| New | +$1.79M |
2025 Q4
0 quarters
|
|
17
Apogee Enterprises
APOG
$865M
| $1.89M | 2.16% |
+25,000
| New | +$945K |
2025 Q4
0 quarters
|
|
18
Zentalis Pharmaceuticals
ZNTL
$202M
| $1.78M | 2.04% |
+1,320,000
| New | +$1.92M |
2025 Q4
0 quarters
|
|
19
Insmed
INSM
$21B
| $1.74M | 1.99% |
+10,000
| New | +$1.82M |
2025 Q4
0 quarters
|
|
20
CALL
Corcept Therapeutics
CORT
$11.9B
| $1.53M | 1.75% |
+44,000
| New | +$3.46M |
2025 Q4
0 quarters
|
|
21
Silence Therapeutics
SLN
$539M
| $1.46M | 1.67% |
+240,000
| New | +$1.54M |
2025 Q4
0 quarters
|
|
22
Edgewise Therapeutics
EWTX
$4.04B
| $1.44M | 1.65% |
+58,000
| New | +$1.16M |
2025 Q4
0 quarters
|
|
23
Beam Therapeutics
BEAM
$2.42B
| $1.39M | 1.58% |
+50,000
| New | +$1.28M |
2025 Q4
0 quarters
|
|
24
Oric Pharmaceuticals
ORIC
$1.28B
| $1.31M | 1.5% |
+160,000
| New | +$1.84M |
2025 Q4
0 quarters
|
|
25
DELISTED
Apellis Pharmaceuticals
APLS
| $1.26M | 1.44% |
+50,000
| New | +$1.17M |
2025 Q4
0 quarters
|
|
Similar funds
SB
WFA
RC
GBFP
KCA
HMS
TH
CWM
Ishara Investments's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Ishara Investments, which disclosed 38 positions worth $87.5M. Its ten largest holdings account for 56% of the portfolio.
Its largest position is Praxis Precision Medicines: 40,000 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 96% of assets, followed by Industrials and Miscellaneous.
- Ishara Investments's largest Q4 2025 buy was Praxis Precision Medicines: 40,000 shares worth $11.8M.
- Ishara Investments's ten largest holdings make up 56% of its $87.5M portfolio in Q4 2025.
- Ishara Investments disclosed 38 positions in Q4 2025, its first 13F filing on record.
Based on Ishara Investments's 13F filing for Q4 2025, filed 17 Feb 2026.